2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMOCompleted
Primary: • To analyze the stability of the MHP using R.S.A to predict the long term survival.Secondary• To analyze the short term (1 year) safety of the MHP compared to the Stanmore hip replacement.• To analyze the short term (1 year) efficacy of…